Lennard-Jones J E
Gut. 1977 Jan;18(1):69-72. doi: 10.1136/gut.18.1.69.
During a six year period 43 patients with Crohns disease were included in a double-blind controlled trial of sulphasalazine given for one year as a possible treatment for reducing the relapse rate after resection or in asymptomatic patients with established disease. No trend in favour of sulphasalazine over the control group was observed. The difficulties of such a trial due to the small number of patients entered from nine hospitals, the varied nature of the disease, and the high incidence of complications, such as intraperitoneal abscess formation, are discussed.
在六年期间，43例克罗恩病患者被纳入一项柳氮磺胺吡啶双盲对照试验，该试验将柳氮磺胺吡啶作为可能的治疗方法，用于降低切除术后或确诊疾病的无症状患者的复发率，疗程为一年。未观察到柳氮磺胺吡啶相对于对照组有任何有利趋势。讨论了由于从九家医院纳入的患者数量较少、疾病性质多样以及并发症（如腹腔脓肿形成）发生率较高而导致该试验面临的困难。
